Reparixin, a CXCR1/2 inhibitor in islet allotransplantation.
Quality of life in Type 1 diabetic patients may be improved with islet transplantation, but lifelong immunosuppression is required to prevent rejection. Allo-immune response is a key player in graft dysfunction and although the adaptive immune response is well characterized, the effect of the innate immune reaction after transplantation is only recently becoming appreciated. In this study, we address how the innate response affects long-term outcomes in a murine islet allotransplant model. CTLA-4 Ig treatment is known to significantly prolong kidney subcapsular islet allograft survival and enhance glucose tolerance. The combination of CTLA-4 Ig with reparixin, which blocks against inflammatory neutrophil infiltration, yielded no long-term graft survival in an intrahepatic allotransplant model but had similar long-term graft survival in the kidney subcapsular model. Seven days after transplant, serum blood IFN-γ levels were significantly lower in the CTLA-4 Ig with reparixin treatment group compared to controls. IL-12p70 cytokine levels were increased with combination treatment, a positive modulation of the inflammatory response to the allograft. Furthermore, KC GRO, also known as CXCL1, was decreased in serum 7 d after transplant. Histologically, we found that immune cell infiltrate, CD4+ and CD8+ T cell populations along with both CXCR1+ and CXCR2+ cell populations were decreased within the CTLA-4 Ig and reparixin islet transplant graft. Overall these data provide insight into the down regulation of T-cell recruitment by CTLA-4 Ig and decreased neutrophil activation and recruitment with reparixin after long-term islet graft survival.
a Alberta Diabetes Institute, University of Alberta , Edmonton , AB , Canada.
Rena L
RL
Pawlick
a Alberta Diabetes Institute, University of Alberta , Edmonton , AB , Canada.
John
J
Wink
a Alberta Diabetes Institute, University of Alberta , Edmonton , AB , Canada.
Andrew R
AR
Pepper
a Alberta Diabetes Institute, University of Alberta , Edmonton , AB , Canada.
Antonio
A
Bruni
a Alberta Diabetes Institute, University of Alberta , Edmonton , AB , Canada.
Nasser
N
Abualhassen
a Alberta Diabetes Institute, University of Alberta , Edmonton , AB , Canada.
Yasmin
Y
Rafiei
a Alberta Diabetes Institute, University of Alberta , Edmonton , AB , Canada.
Boris
B
Gala-Lopez
a Alberta Diabetes Institute, University of Alberta , Edmonton , AB , Canada.
Mariusz
M
Bral
a Alberta Diabetes Institute, University of Alberta , Edmonton , AB , Canada.|b Clinical Islet Transplant Program, University of Alberta , Edmonton , AB , Canada.
A M James
AM
Shapiro
D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000276:immunology / Q000601:surgery*; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology / Q000601:surgery*; D005951:Glucose Tolerance Test; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control*; D006085:Graft Survival / Q000187:drug effects* / Q000276:immunology; D016381:Islets of Langerhans Transplantation / Q000276:immunology / Q000379:methods*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use*
D013449:Sulfonamides; C490707:reparixin
Allo rejection; CTLA-4 Ig; diabetes; islet; reparixin; transplant